(Q39167351)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23582185%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

title

Secondary c-Kit mutations confer acquired resistance to RTK inhibitors in c-Kit mutant melanoma cells (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23582185%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23582185%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Richard F. Kefford

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23582185%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Helen Rizos

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23582185%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

author name string

Jason R Todd

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23582185%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

publication date

13 May 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23582185%20AND%20SRC:MED&resulttype=core&format=json

Pigment Cell & Melanoma Research

28 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23582185%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

volume

26

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23582185%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23582185%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

page(s)

518-526

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23582185%20AND%20SRC:MED&resulttype=core&format=json

Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation

28 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12107

L576P KIT mutation in anal melanomas correlates with KIT protein expression and is sensitive to specific kinase inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12107

Therapeutic targeting of c-KIT in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12107

Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12107

KIT gene mutations and copy number in melanoma subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12107

Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12107

Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12107

KIT as a therapeutic target in metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12107

A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12107

Nilotinib in patients with metastatic melanoma harboring KIT gene aberration

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12107

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12107

Activate and resist: L576P-KIT in GIST.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12107

Molecular pathobiology of gastrointestinal stromal sarcomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12107

Preclinical evaluation of nilotinib efficacy in an imatinib-resistant KIT-driven tumor model

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12107

Distinct sets of genetic alterations in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12107

Somatic activation of KIT in distinct subtypes of melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12107

Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12107

Mechanisms of oncogenic KIT signal transduction in primary gastrointestinal stromal tumors (GISTs).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12107

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12107

Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12107

KIT as a therapeutic target in melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12107

The role of the molecular footprint of EGFR in tailoring treatment decisions in NSCLC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12107

Molecular basis for primary and secondary tyrosine kinase inhibitor resistance in gastrointestinal stromal tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12107

Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12107

Oncogene-induced senescence does not require the p16(INK4a) or p14ARF melanoma tumor suppressors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12107

Clinical responses observed with imatinib or sorafenib in melanoma patients expressing mutations in KIT

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12107

Molecular correlates of imatinib resistance in gastrointestinal stromal tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12107

Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12107

The phosphatidyl inositol 3-kinase pathway is central to the pathogenesis of Kit-activated melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12107

Heterogeneity of kinase inhibitor resistance mechanisms in GIST

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12107

Sunitinib therapy for melanoma patients with KIT mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12107

KRAS and BRAF mutations predict primary resistance to imatinib in gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12107

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12107

Protein kinase C-theta regulates KIT expression and proliferation in gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12107

Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12107

C-kit protein expression correlated with activating mutations in KIT gene in oral mucosal melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12107

Gastrointestinal stromal tumour.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12107

Analysis of c-KIT expression and KIT gene mutation in human mucosal melanomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12107

Phase 2 study of nilotinib as third-line therapy for patients with gastrointestinal stromal tumor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12107

Activating c-KIT mutations in a subset of thymic carcinoma and response to different c-KIT inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12107

Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12107

The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12107

Major response to everolimus in melanoma with acquired imatinib resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12107

Imatinib: a review of its use in the management of gastrointestinal stromal tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12107

Improved insight into resistance mechanisms to imatinib in gastrointestinal stromal tumors: a basis for novel approaches and individualization of treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12107

MEK inhibitor enhances the inhibitory effect of imatinib on pancreatic cancer cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12107

The MAPK pathway functions as a redundant survival signal that reinforces the PI3K cascade in c-Kit mutant melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12107

Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12107

Mechanisms of resistance to imatinib and sunitinib in gastrointestinal stromal tumor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12107

Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12107